Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (Cabometyx®) for the Treatment of Patients With Previously Treated Advanced Neuroendocrine Tumors
伊克力西斯提供關於Cabozantinib（Cabometyx®）用於治療先前治療過的晚期神經內分泌腫瘤的補充新藥申請的監管更新
